Physician profile
Greg J Deters
NPI 1497861702
$7,258.51
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $1,026 · 2021: $1,238 · 2022: $1,271 · 2023: $1,665 · 2024: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,069.34 | 2019-2024 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $971.58 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $823.23 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $798.72 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Novartis Pharmaceuticals Corporation | $600.64 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.35 | 2019-2024 | Synjardy, Jardiance, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $252.38 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.11 | 2019-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $198.98 | 2019-2022 | |
| Amgen INC. | $197.04 | 2019-2024 | Evenity, Prolia, Otezla |
| Dexcom, INC. | $161.98 | 2021-2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $155.56 | 2019-2023 | Yupelri |
| Abbott Laboratories | $148.80 | 2020-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $146.45 | 2020-2022 | |
| Abbvie INC. | $143.67 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Deters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.